Hemab Therapeutics Holdings, a clinical-stage biotech based in Cambridge, MA, announced IPO terms on April 27, 2026, planning to raise approximately $200 million12
The company is offering 11.8 million shares at a price range of $16 to $18 per share, with an expected midpoint valuation of $199.92 million25
Hemab's lead candidate, sutacimig (HMB-001), has completed Phase 2 trials and is ready for Phase 3 testing for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency2
The company's second candidate, HMB-002, is in Phase 1/2 trials for Von Willebrand Disease2
Hemab will trade on the Nasdaq under the ticker symbol COAG2
Goldman Sachs, Jefferies, and Evercore ISI are the joint bookrunners for the IPO2
The company was founded in 2020 and has 72 employees5
Hemab expects to spend $120-$130 million on its lead program, $60-$70 million for HMB-002, and $25-$35 million for additional programs4
The IPO is expected to price the week of April 27, 2026, with trading expected to begin on May 1, 20265
Sources:
1. https://firstwordpharma.com/story/7226402
2. https://www.renaissancecapital.com/IPO-Center/News/118571/Coagulation-disorder-biotech-Hemab-Therapeutics-Holdings-sets-terms-for-$20
4. https://www.fiercebiotech.com/biotech/seaport-hemab-chart-courses-180m-ipos-fund-depression-clotting-candidates